A Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety Tolerability and Efficacy of IMB-1018972 in Patients with Non-obstructive Hypertrophic Cardiomyopathy
Brief description of study
This study will examine the effect of IMB-1018972 on exercise capacity and how the heart uses energy. IMB-1018972 is a research drug because it has not been approved by the Food and Drug Administration. It is being developed by Imbria Pharmaceuticals Inc., which is the sponsor of this study and pays for the study to be conducted. The primary objective of the study is to evaluate the safety and tolerability of the study drug and to assess whether treatment with the study drug can improve how the hearts of subjects with nonobstructive hypertrophic cardiomyopathy use energy.
Clinical Study Identifier: s21-00992
ClinicalTrials.gov Identifier: NCT04826185
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
